A 5-aza-2′-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma

European Respiratory Journal

Volumn 38, Issue 5, 2011, Pages 1105-1116

  Leclercq, S ^a   Gueugnon, F ^a   Boutin, B ^a   Guillot, F ^a   Blanquart, C ^a   Rogel, A ^a   Padieu, M ^a   Pouliquen, D ^a   Fonteneau, J F ^a   Gregoire M ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

5 aza 2 deoxycytidine; Immunotherapy; Mesothelioma; Suberoylanilide hydroxamic acid; Tumour antigen; Valproic acid

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CD8 ANTIGEN; GAMMA INTERFERON; HLA A ANTIGEN; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; NY ESO 1 ANTIGEN; TUMOR ANTIGEN; VALPROIC ACID; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL DEATH; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DISEASE MODEL; DRUG CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; MOLECULAR RECOGNITION; NONHUMAN; PLEURA MESOTHELIOMA; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA MODIFICATION METHYLASES; DRUG SYNERGISM; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MEMBRANE PROTEINS; MESOTHELIOMA; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PLEURAL NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; VALPROIC ACID;

EID: 80355127134     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00081310     Document Type: Article

References (40)

1. Kazan-Allen L. Asbestos and mesothelioma: worldwide trends. Lung Cancer 2005; 49: Suppl. 1, S3-S8. (Pubitemid 40798835)
2. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005; 5: 397-408. (Pubitemid 41073959)
3. Wijermans PW, Ruter B, Baer MR, et al. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res 2008; 32: 587-591. (Pubitemid 351248959)
4. Schrump DS, Fischette MR, Nguyen DM, et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 2006; 12: 5777-5785. (Pubitemid 44629609)
5. Mann BS, Johnson JR, Cohen MH, et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007; 12: 1247-1252. (Pubitemid 350106355)
6. Garcia-Manero G, Yang H, Bueso-Ramos C, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid (SAHA)) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008; 111: 1060-1066. (Pubitemid 351213383)
7. Kuendgen A, Gattermann N. Valproic acid for the treatment of myeloid malignancies. Cancer 2007; 110: 943-954. (Pubitemid 47312858)
8. Vandermeers F, Hubert P, Delvenne P, et al. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin Cancer Res 2009; 15: 2818-2828.
9. Krug LM, Curley T, Schwartz L, et al. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 2006; 7: 257-261. (Pubitemid 43280028)
10. Paik PK, Krug LM. Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials. J Thorac Oncol 2010; 5: 275-279.
11. Siegel D, Hussein M, Belani C, et al. Vorinostat in solid and hematologic malignancies. J Hematol Oncol 2009; 2: 31.
12. Plimack ER, Kantarjian HM, Issa JP. Decitabine and its role in the treatment of hematopoietic malignancies. Leuk Lymphoma 2007; 48: 1472-1481. (Pubitemid 47272797)
13. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009; 27: 5459-5468.
14. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005; 23: 3923-3931. (Pubitemid 46218695)
15. Robinson BW, Robinson C, Lake RA. Localised spontaneous regression in mesothelioma - possible immunological mechanism. Lung Cancer 2001; 32: 197-201. (Pubitemid 32372611)
16. Gregoire M. What's the place of immunotherapy in malignant mesothelioma treatments? Cell Adh Migr 2009; 4: 153-161.
17. Weber J, Salgaller M, Samid D, et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2′-deoxycytidine. Cancer Res 1994; 54: 1766-1771.
18. Ying J, Gao Z, Li H, et al. Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies. Br J Haematol 2007; 136: 829-832. (Pubitemid 46348417)
19. Sigalotti L, Coral S, Altomonte M, et al. Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. Br J Cancer 2002; 86: 979-982. (Pubitemid 34271036)
20. Natsume A, Wakabayashi T, Tsujimura K, et al. The DNA demethylating agent 5-aza-29-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Int J Cancer 2008; 122: 2542-2553. (Pubitemid 351590488)
21. Weiser TS, Guo ZS, Ohnmacht GA, et al. Sequential 5-aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J Immunother 2001; 24: 151-161. (Pubitemid 32183061)
22. Gueugnon F, Leclercq S, Blanquart C, et al. Identification of novel markers for the diagnosis of malignant pleural mesothelioma. Am J Pathol 2011; 178: 1033-1042.
23. Fonteneau JF, Larsson M, Somersan S, et al. Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells. J Immunol Methods 2001; 258: 111-126. (Pubitemid 33016531)
24. Moalli PA, MacDonald JL, Goodglick LA, et al. Acute injury and regeneration of the mesothelium in response to asbestos fibers. Am J Pathol 1987; 128: 426-445. (Pubitemid 17139894)
25. Goto Y, Shinjo K, Kondo Y, et al. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Res 2009; 69: 9073-9082.
26. Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the reexpression of genes silenced in cancer. Nat Genet 1999; 21: 103-107. (Pubitemid 29036293)
27. Steiner FA, Hong JA, Fischette MR, et al. Sequential 5-aza 2′- deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells. Oncogene 2005; 24: 2386-2397. (Pubitemid 40546697)
28. Gnjatic S, Nishikawa H, Jungbluth AA, et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 2006; 95: 1-30. (Pubitemid 44088423)
29. Guo ZS, Hong JA, Irvine KR, et al. De novo induction of a cancer/ testis antigen by 5-aza-29-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res 2006; 66: 1105-1113. (Pubitemid 43165979)
30. Kristensen LS, Nielsen HM, Hansen LL. Epigenetics and cancer treatment. Eur J Pharmacol 2009; 625: 131-142.
31. Santi DV, Garrett CE, Barr PJ. On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs. Cell 1983; 33: 9-10. (Pubitemid 13096428)
32. Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem 2001; 70: 81-120. (Pubitemid 32662206)
33. Marks PA, Miller T, Richon VM. Histone deacetylases. Curr Opin Pharmacol 2003; 3: 344-351. (Pubitemid 36908937)
34. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009; 100: 2014-2021.
35. Oi S, Natsume A, Ito M, et al. Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2′-deoxycytidine in glioma cells. J Neurooncol 2009; 92: 15-22.
36. Cordier Kellerman L, Valeyrie L, Fernandez N, et al. Regression of AK7 malignant mesothelioma established in immunocompetent mice following intratumoral gene transfer of interferon-γ. Cancer Gene Ther 2003; 10: 481-490. (Pubitemid 36667135)
37. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 2006; 108: 3271-3279.
38. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, et al. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 2008; 34: 206-222.
39. Atmaca A, Al-Batran SE, Maurer A, et al. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 2007; 97: 177-182. (Pubitemid 47057472)
40. Castagneto B, Zai S, Mutti L, et al. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: results of a phase II study on 31 consecutive patients. Lung Cancer 2001; 31: 303-310. (Pubitemid 32107025)